HLS Therapeutics Inc represents values of integrity, innovation, and commitment to improving patients' lives. With a corporate philosophy focused on enhancing healthcare outcomes, they strive to develop and commercialize innovative therapies to address unmet medical needs. HLS Therapeutics Inc prioritizes patient safety, efficient operations, and collaboration with healthcare professionals to deliver high-quality treatments. By leveraging their expertise and building strategic partnerships, HLS Therapeutics Inc aims to create sustainable value for shareholders while making a positive impact on the healthcare industry.

HLS Therapeutics Inc is primarily present in Canada and the United States.

HLS Therapeutics Inc has achieved significant milestones in its development. Some of these key achievements include securing regulatory approvals for its leading pharmaceutical products, such as Vascepa® and Cortiment®. The company has also expanded its market presence through strategic partnerships, collaborations, and acquisitions. In addition, HLS Therapeutics Inc has demonstrated consistent revenue growth and achieved positive clinical trial results, reinforcing its position as an innovative player in the pharmaceutical industry. The company's commitment to advancing patient care and its strong product portfolio have contributed to its success in improving healthcare outcomes.

HLS Therapeutics Inc is a pharmaceutical company with a rich history and background. Established in (year), HLS Therapeutics has been dedicated to improving patient outcomes and enhancing quality of life. The company specializes in the development and commercialization of innovative therapies for various medical conditions. HLS Therapeutics has achieved significant milestones, such as (mention significant achievements or product launches), contributing to its reputation as a leader in the industry. With its unwavering commitment to research, development, and patient care, HLS Therapeutics continues to make strides in advancing healthcare solutions and remains at the forefront of the pharmaceutical sector.

The main competitors of HLS Therapeutics Inc in the market include companies like ABC Pharmaceuticals, XYZ Therapeutics, and DEF Health Sciences.

HLS Therapeutics Inc is primarily active in the pharmaceutical industry.

The business model of HLS Therapeutics Inc focuses on commercializing and acquiring innovative healthcare products and technologies. With a patient-centric approach, HLS Therapeutics aims to improve the lives of individuals by providing effective treatment options across different therapeutic areas. The company strategically identifies and partners with like-minded organizations, leveraging their expertise and market presence to drive growth. HLS Therapeutics emphasizes on marketing and promotion, ensuring wide accessibility to its products. By continuously assessing and expanding its product portfolio, HLS Therapeutics strives to deliver value to patients, healthcare professionals, and shareholders.

Коефициентът на цена спрямо печалбата (КЦП) на HLS Therapeutics е -4,07.

Коефициентът на цена към оборот (KUV) на HLS Therapeutics е 1,30.

AlleAktien качественият резултат за HLS Therapeutics е 1/10.

очаквана HLS Therapeutics оборотът е 57,73 млн. USD.

очаквана HLS Therapeutics печалба е -18,46 млн. USD.

HLS Therapeutics Inc is a Canadian company specializing in the development and marketing of innovative products for rare diseases and chronic conditions. The company operates in two divisions: Medical Products and Specialty Pharmaceuticals. Its medical products include drugs for the treatment of cancer, autoimmune diseases, and rare diseases. HLS Therapeutics also develops biosimilars as cost-effective alternatives to expensive biologics. Its specialty pharmaceuticals focus on treating central nervous system disorders, including epilepsy and neuropathy, as well as cardiovascular diseases and cholesterol reduction. Some of its well-known products include Cortef for adrenal insufficiency treatment and Vascepa, an Omega-3 fatty acid ester for triglyceride reduction. The company's business model is based on researching and developing therapies for unmet medical needs and marketing them in North America and Europe. HLS Therapeutics collaborates closely with research and healthcare partners and has a high success rate in product approvals. It has an experienced leadership team and a strong network of physicians, scientists, and research institutions, allowing for continuous expansion of its innovative product pipeline. While prioritizing patient needs and delivering positive patient experiences, HLS Therapeutics follows a growth strategy through organic development, market expansion, strategic acquisitions, and partnerships. With its focus on meeting unmet medical needs, strong R&D capabilities, high-quality products, and innovative growth strategies, HLS Therapeutics is poised to remain a leader in the industry.

HLS Therapeutics разпределя дивидента от 0,20 USD на плащания годишно.

Дивидентата за HLS Therapeutics в момента не може да бъде изчислена или компанията не разпределя дивиденти.

ISIN на HLS Therapeutics е CA40390B1094.

WKN на HLS Therapeutics е A2JGH0.

Тикерът на HLS Therapeutics е HLS.TO.

През последните 12 месеца HLS Therapeutics изплати дивиденда в размер на 0,20 USD . Това съответства на дивидендна доходност от около 8,58 %. За следващите 12 месеца се очаква HLS Therapeutics да изплати дивиденда в размер на 0,18 USD.

Дивидентната доходност на HLS Therapeutics в момента е 8,58 %.

HLS Therapeutics изплаща дивидент на тримесечие. Той се разпределя в месеците август, ноември, февруари, май.

HLS Therapeutics платеше дивиденда всяка година през последните 0 години.

За идните 12 месеца се очакват дивиденти в размер на 0,18 USD. Това съответства на дивидентна доходност от 7,90 %.

HLS Therapeutics се отнася за сектор 'Здраве'.

За да получите последното дивидентно плащане от HLS Therapeutics на 15.06.2023 г. в размер на 0,05 USD, трябваше да притежавате акцията в портфейла си преди Ex-деня на 27.04.2023 г..

Последното дивидентно плащане беше извършено на 15.06.2023 г..

През година 2023 HLS Therapeutics изплати 0,2 USD под формата на дивиденти.

Дивидентите от HLS Therapeutics се изплащат в USD.